Latest news
Published: 20th February 2025
Oxford Drug Design awarded £1m PACE funding to progress uUTI treatment
As part of company’s tRNA synthetase development in oncology and infections 20th February 2025, United Kingdom: Oxford Drug Design has been awarded £1m in funding to progress its uUTI (uncomplicated urinary tract infection) antibacterial programme, as announced by PACE (Pathways to
Published: 15th January 2025
Oxford Drug Design achieves further in vivo validation of novel approach against multiple tumours
United Kingdom, 15th January 2025: Oxford Drug Design, the Oxford-based AI drug discovery company, has today announced additional in vivo validation for its first-in-class approach against cancer as the Company continues to apply its pioneering AI platform to develop novel treatments in oncology
Published: 26th September 2024
Oxford Drug Design awarded share of £3m Cystic Fibrosis Collaborative Drug Discovery Programme
The cross-sector initiative provides funding and support to accelerate new treatments for lung infections in Cystic Fibrosis September 26th 2024, United Kingdom: Oxford Drug Design is among the first three companies to be awarded a share of a £3 million Collaborative Discovery Programme (CDP)
Asset bank
For any additional information from Oxford Drug Design :
+44 7920 792183Oxforddrugdesign@headonpr.co.uk